Results 111 to 120 of about 135,075 (307)

Heterologous Prime-Boost with ChAdOx1-VZV Establishes Dual-Layer Immunogenicity Conferring Protective Potential Against Herpes Zoster

Vaccines
Background/Objectives: Varicella-zoster virus (VZV) causes herpes zoster (HZ/shingles), particularly in older adults with weakened cell-mediated immunity (CMI), which is essential for controlling VZV reactivation and reducing HZ severity.
Jiayu Zhao, Juan Shao, Xiuwen Sui, Menghan Wei, Xinjian Ma, Zhijun Xu, Tao Zhu   +6 more
doaj   +1 more source

Toward Effective Competition in Biologics

, 2019
In a previous article—Follow-On Biologics Are Set Up to Fail—I explained why biologics markets do not and probably will not have enough competition. This is not to say that these markets lack competition altogether.
Heled, Yaniv
core  

From junk to function — How weak selection in eukaryotes builds new parts and drives genomic complexity

FEBS Letters, EarlyView.
How do genomes gain new functional parts? In eukaryotes, which tend to evolve under weak selection, much of the genome is junk. Palazzo and Qiu borrow the logic of Markov chains to show how non‐functional DNA becomes functional through the appearance of intermediate states, which arise due to epistasis, buffering, and biochemical messiness, allowing ...
Alexander F. Palazzo, Yi Qiu
wiley   +1 more source

The Shewanella oneidensis Fic enzyme SoFic targets the switch‐I region of EF‐Tu for AMPylation

FEBS Letters, EarlyView.
Fic enzymes mediate diverse post‐translational modifications across all domains of life, including AMPylation. Prokaryotic EF‐Tu can be AMPylated and deAMPylated by the conserved Fic enzyme SoFic. Structural and biochemical approaches were used to characterize the effect of AMPylation on EF‐Tu, SoFic's enzymatic activities, and the enzyme‐target ...
Svenja Runge, Vivian Pogenberg, Alexander Baumgart, Bente Siebels, Hartmut Schlüter, Michael Hecht‐Bucher, Aymelt Itzen   +6 more
wiley   +1 more source

Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics /

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products.
Herzyk, Danuta J.,editor., Plitnick, Lisa M.,editor.   +1 more
core  

Biologics and public health: Prospects and challenges

, 2018
Owoeye, OA ORCiD: 0000-0001-8716-2886Biotechnology has been used by humankind for thousands of years and it remains a very important part of human medicine.
Owoeye, Olasupo A, O Owoeye (10000085), Olasupo Owoeye (9824543), Owoeye, Oluwabusayo   +3 more
core  

Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis. [PDF]

BACKGROUND: Primary sclerosing cholangitis (PSC) is an immune-mediated, chronic cholestatic liver disease. Currently, liver transplantation is the only established life-saving treatment.
Fairlie, Thomas, Jones, Michael P, OBeirne, James, Gores, Gregory J, Ma, Xiaomin, Culver, Emma L, Shah, Ayesha, Jones, Michael, Gores, Gregory, Tabibian, James H, Dignass, Axel, Callaghan, Gavin, Culver, Emma, Stuart, Katherine, Canbay, Ali, De Cruz, Peter, Holtmann, Gerald J, O’Beirne, James, Tabibian, James, Holtmann, Gerald   +19 more
core   +1 more source

Chiral separation of chloroalkanes with the chromatographic column onboard Martian rovers

FEBS Letters, EarlyView.
Computer image of the Rosalind Franklin Rover of ESA's ExoMars mission. ExoMars is scheduled to land on planet Mars in Oxia Planum in 2029. This area represents an interesting spot to look for biosignatures. Investigations of ExoMars include measurement on molecular chirality. We show that chiral chloroalkanes, that have been identified on Mars, can be
Asma Merzougui, Agnes Banreti, Armelle L. Ernst, Guillaume Leseigneur, Uwe J. Meierhenrich   +4 more
wiley   +1 more source

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning

mAbs
Antibody polyreactivity, which is characterized by broad, low-affinity off-target binding, is an undesirable drug property associated with rapid clearance.
Matthew Saunders, Sophie Comyn, Borka Medjo, Zahra Anderson, Chase LaCombe, Jake Ripley, Kyra Chapman, Tim Ma, Abigail Ventura, Alyssa Ruelos, Alec Jaeger, Chase Poindexter, Ophelia Rebanal, Nemanja Vucic, Sean M. West, David Eavarone, John M. Sutton, Douglas Ganini da Silva, David A. Spencer   +18 more
doaj   +1 more source

Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network

, 2014
Contains fulltext : 136766.pdf (Publisher’s version ) (Open Access)BACKGROUND: Although the effectiveness of biologics for psoriasis has been measured extensively with objective outcome measures, studies based on subjective, patient ...
Jong, E.M.G.J. de, Kuijpers, A.L.A., Zweegers, J., Arnold, W.P., Kievit, W., Koetsier, M.I.A., Kooijmans, M.E., Andriessen, M.P.M., Reek, J.M.P.A. van den, Njoo, M.D., Ossenkoppele, P.M., Lumig, P.P.M. van, Seyger, M.M.B., Mommers, J.M., Kerkhof, P.C.M. van de, Sybrandy-Fleuren, B.A.M.   +15 more
core   +1 more source